Vicore Pharma Holding AB (VCRE) Stock Analysis
Verdict: AVOID
Massive cash burn and extreme post-IPO volatility outweigh clinical potential until Phase 2b/3 data or a clear floor is established.
Investment score: 38/100
Analysis as of
Is Vicore Pharma Holding AB stock worth reviewing? The TradeMates thesis
Vicore Pharma exhibits classic pre-revenue biotech risk: high innovation potential coupled with unsustainable cash burn and violent price swings.
7-factor investment score
- Valuation: 20/100 (weight 20%)
- Financial Health: 45/100 (weight 15%)
- Technical Momentum: 15/100 (weight 15%)
- Earnings Quality: 30/100 (weight 15%)
- Insider Sentiment: 50/100 (weight 10%)
- Analyst Consensus: 50/100 (weight 10%)
- Risk-Adjusted Return: 25/100 (weight 15%)
Vicore Pharma Holding AB opportunities and risks
What speaks for VCRE
- First-in-class AT2R Platform
What speaks against VCRE
- Capital Exhaustion Runway
Frequently asked questions about Vicore Pharma Holding AB (VCRE)
Is VCRE stock a good investment?
The TradeMates model rates Vicore Pharma Holding AB as AVOID with an investment score of 38/100. Vicore Pharma exhibits classic pre-revenue biotech risk: high innovation potential coupled with unsustainable cash burn and violent price swings. This is algorithmic model output, not personal investment advice.
Is VCRE stock a buy?
The TradeMates model verdict for VCRE is AVOID with an investment score of 38/100. Treat this as a model signal to review, not a personal buy recommendation.